Table 3.
Pap class distribution of included patients of which test results of all 3 assays are available (n = 11,333).
| Pap class | Bethesda classification | Included samples (N) | Pap class distribution of tested cohort (DuSC) | Pap class distribution of Dutch screening populationa | HC2 hrHPV prevalence %(N) |
cobas hrHPV prevalence %(N) |
Aptima hrHPV prevalence %(N) |
Overall hrHPV prevalence |
|---|---|---|---|---|---|---|---|---|
| 0 | - | 191 | 1.7% | 1.7% | 6.8% (13) | 5.2% (10) | 4.2% (8) | 5.4 ± 1.3% |
| 1 | Normal | 10,639 | 93.9% | 93.6% | 5.8% (620) | 5.7% (609) | 5.1% (545) | 5.5 ± 0.4% |
| 2 | ASC-US | 314 | 2.8% | 3.0% | 47.8% (150) | 41.1% (129) | 39.5% (124) | 42.8 ± 4.4% |
| 3a1 | LSIL | 71 | 0.6% | 0.7% | 91.5% (65) | 85.9% (61) | 84.5% (60) | 87.3 ± 3.7% |
| 3a2 | HSIL (moderate) | 50 | 0.4% | 0.4% | 94.0% (47) | 94.0% (47) | 94.0% (47) | 94.0 ± 0.0% |
| 3b | HSIL (severe) | 62 | 0.5% | 0.6% | 95.2% (59) | 93.5% (58) | 96.8% (60) | 95.2% ± 1.7% |
| 4 | CIS/AIS | 6 | 0.01% | 0.0% | 83.3% (5) | 83.3% (5) | 83.3% (5) | 83.3 ± 0.0% |
| Total (N) | 11,333 | 959 | 919 | 849 |
Number of included samples per Pap class and Pap class distribution of study cohort vs Pap class distribution of the Dutch screening program; and hrHPV prevalences per assay and overall mean
Pap 0 = sample inadequate for cytology
aBased on the Dutch national pathology registry (PALGA database)
ASC-US Atypical Squamous Cells of Undetermined Significance, LSIL Low-grade Squamous Intraepithelial Lesion, HSIL High-grade Squamous Intraepithelial Lesion, CIS Carcinoma in situ, AIS Adenocarcinoma in situ